Vaccination of the global population against COVID-19 is a great scientific, logistical, and
moral challenge. Despite the rapid development and authorization of several full-length …

The rapid development and deployment of mRNA and adenovirus-vectored vaccines
against coronavirus disease 2019 (COVID-19) continue to astound the global scientific …

Recombinant proteins (RP) are widely used as biopharmaceuticals, industrial enzymes, or
sustainable food source. Yeasts, with their ability to produce complex proteins through a …

Background We assessed the efficacy of a receptor-binding domain (RBD)-based protein
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 …

There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low-
and middle-income countries. Here, we report on the development of a SARS-CoV-2 …

Massive production of efficacious SARS-CoV-2 vaccines is essential for controlling the
ongoing COVID-19 pandemic. We report here the preclinical development of yeast …

Introduction The development of a yeast-expressed recombinant protein-based vaccine
technology co-developed with LMIC vaccine producers and suitable as a COVID-19 vaccine …

Diagnostics and drug delivery technologies engineered for low-resource settings aim to
meet their technical design specifications using strategies that are compatible with limited …

SARS-CoV-2 protein subunit vaccines are currently being evaluated by multiple
manufacturers to address the global vaccine equity gap, and need for low-cost, easy to …

Optimum formulation of Biological-E's protein subunit CORBEVAX™ vaccine was selected
in phase-1 and-2 studies and found to be safe and immunogenic in healthy adult population …